KR101978365B1 - Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract - Google Patents
Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract Download PDFInfo
- Publication number
- KR101978365B1 KR101978365B1 KR1020170180383A KR20170180383A KR101978365B1 KR 101978365 B1 KR101978365 B1 KR 101978365B1 KR 1020170180383 A KR1020170180383 A KR 1020170180383A KR 20170180383 A KR20170180383 A KR 20170180383A KR 101978365 B1 KR101978365 B1 KR 101978365B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- periodontal disease
- treatment
- prevention
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 52
- 241000206608 Pyropia tenera Species 0.000 title claims abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 15
- 241000195493 Cryptophyta Species 0.000 claims abstract description 6
- 229940034610 toothpaste Drugs 0.000 claims abstract description 3
- 239000000606 toothpaste Substances 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims description 32
- 210000002950 fibroblast Anatomy 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 7
- 235000021109 kimchi Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000015340 Arenaria serpyllifolia Nutrition 0.000 claims description 4
- 241001365715 Arenaria serpyllifolia Species 0.000 claims description 4
- 241000242303 Codium cylindricum Species 0.000 claims description 4
- 241000196222 Codium fragile Species 0.000 claims description 4
- 241000989762 Monostroma nitidum Species 0.000 claims description 4
- 244000124853 Perilla frutescens Species 0.000 claims description 4
- 241000015177 Saccharina japonica Species 0.000 claims description 4
- 241001261506 Undaria pinnatifida Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 235000004348 Perilla frutescens Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 239000000668 oral spray Substances 0.000 abstract description 4
- 229940041678 oral spray Drugs 0.000 abstract description 3
- 235000015218 chewing gum Nutrition 0.000 abstract description 2
- 229940112822 chewing gum Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 11
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 235000007516 Chrysanthemum Nutrition 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000003239 periodontal effect Effects 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 description 5
- 239000000551 dentifrice Substances 0.000 description 5
- 229940069445 licorice extract Drugs 0.000 description 5
- 241001474374 Blennius Species 0.000 description 4
- 241000202807 Glycyrrhiza Species 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241001164374 Calyx Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241001468191 Lactobacillus kefiri Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 240000000366 Melilotus officinalis Species 0.000 description 2
- 235000017822 Melilotus officinalis Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 235000006964 Perilla frutescens var acuta Nutrition 0.000 description 2
- 240000001979 Perilla frutescens var. acuta Species 0.000 description 2
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 2
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000199899 Alariaceae Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000254171 Curculionidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000206671 Gelidium amansii Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007058 Halophila ovalis Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194038 Lactococcus plantarum Species 0.000 description 1
- 241000194037 Lactococcus raffinolactis Species 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 241000199900 Laminariales Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical class OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Chemical class OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical class [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Chemical class OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 208000006860 root resorption Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical class [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 김 추출물을 포함하는 치주 질환 예방 및 치료용 조성물에 관한 것이다. 보다 구체적으로 김 추출물의 치은섬유아세포(HGF-1, Human Gingival Fibroblast-1)의 염증을 완화할 수 있는 치주 질환 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of periodontal disease including a Kim extract. More specifically, the present invention relates to a composition for preventing and treating periodontal disease, which can alleviate inflammation of gingival fibroblast (HGF-1, Human Gingival Fibroblast-1).
치주조직은 치조골, 치은(잇몸) 및 치주인대로 이루어져 있다. 잇몸은 우리가 입안에서 볼 수 있는 치아 지지조직의 일부분으로 여기서 질환(치은염)이 시작되는데, 질환이 심화되어 지지조직으로 점점 깊게 퍼져나가면 치아 뿌리면과 치아를 둘러 싸고 있는 뼈 조직에 결합되어 있는 치주인대가 파괴되고 치아를 싸고 있는 치조골도 파괴되면서 치주병이 발생하게 된다.Periodontal tissue consists of alveolar bone, gingiva (gums) and periodontal ligament. The gingiva is a part of the tooth supporting tissue that we can see in the mouth. The disease (gingivitis) starts here. When the disease deepens and spreads deeply into the supporting tissue, the periodontal ligament attached to the bone tissue surrounding the tooth root The ligament is destroyed and the alveolar bone surrounding the tooth is destroyed, causing periodontal disease.
치은염 및 치주병을 포함하는 치주질환은 세균에 의해 야기되는 치아지지 조직의 염증상태로서, 출혈, 치주낭의 형성 및 치조골의 파괴 등으로 인하여 치아의 상실을 가져오는 질환이다. 이러한 치주질환은 세균의 집락형성, 세균의 치주조직 침투 및 치주조직 파괴의 과정으로 진행된다. Periodontal disease, including gingivitis and periodontal disease, is an inflammatory state of the tooth supporting tissues caused by bacteria, which causes loss of teeth due to bleeding, formation of the periodontal pouch, and destruction of the alveolar bone. This periodontal disease progresses to bacterial colony formation, bacterial infiltration of periodontal tissue, and periodontal tissue destruction.
구체적으로, 불량한 구강 위생 상태로 인하여 구강 세균이 치면 세균막을 형성하면 염증이 생겨 가끔 잇몸에서 피가 나고 구취가 나며, 이러한 상태로 더 진행되면 치아와 잇몸 사이의 벌어진 틈이 더 깊어져서 치주낭이 생기고, 여기에 치주질환을 일으키는 세균들이 번식하여 치주염이 발생된다. Specifically, when the oral bacteria are formed due to a poor oral hygiene condition, a bacterial membrane is formed. When the bacteria form, the blood gushes from the gums and the bad breath develops. In this state, the gap between the tooth and the gum becomes deeper, , Which causes bacteria that cause periodontal disease, resulting in periodontitis.
치주염이 진행되면 칫솔 질과 같은 약한 자극에도 잇몸에서 피가 나기도 하며 붓고, 종종 급성염증으로 변화되어 통증을 유발한다. 이러한 염증은 교원질, 칼슘 및 인의 침척물(hydroxyapatite)로 단단한 뼈를 만드는 조골세포(osteoblast)의 골을 만드는 기능을 저하시키고, 파골세포(osteoclast)의 뼈를 파괴 또는 흡수(resorption)하는 작용이 높아져서 치조골이 점점 낮아지고 파괴되어 결국 치아를 상실하게 된다. If periodontitis develops, weak stimuli such as toothbrushing may cause bleeding from the gums, swelling, and often acute inflammation leading to pain. These inflammations are caused by the action of collagen, calcium, and phosphorus (hydroxyapatite) to reduce the ability to make bone in osteoblasts that make hard bones, and to destroy or resorb bone in osteoclasts The alveolar bone is gradually lowered and destroyed, eventually resulting in tooth loss.
이때, 파골세포는 골수 내의 단핵구/대식세포 계통의 세포로부터 유래하고, 이 단핵전구세포 는 혈액 내로 순환되며 골내막층에서 전구세포들이 증식되어 다핵세포를 형성하기 위해 융합된다고 알려져 있으며(Scheven, B. A. A. et al., Nature, 321:79-81, 1986), 파골세포에는 특징적으로 타르트레이트(tartrate)에 대해 저항성을 나타내는 산성 포스파타제(acid phosphatase)인 TRAP(tartrate-resistant acid phosphatase)을 가지며 이는 다른 골 조직 세포와 구별할 수 있는 파골세포의 세포화학적 표지효소로 이용된다고 알려져 있다(Minkin, C., Calcif. Tissue Int., 34:285-290, 1982).At this time, it is known that osteoclasts are derived from monocyte / macrophage lineage cells in the bone marrow, and these mononuclear progenitor cells circulate in the blood and progenitor cells are proliferated in the endosteal layer and fused to form polynuclear cells (Scheven, BAA et al., Nature, 321: 79-81, 1986), osteoclasts have a tartrate-resistant acid phosphatase (TRAP), an acid phosphatase characteristic of tartrate resistance, (Minkin, C., Calcif. Tissue Int., 34: 285-290, 1982). It is known to be used as a cytochemical labeling enzyme for osteoclast differentiating from tissue cells.
치주질환의 원인은 여러 가지가 있으나, 국소적 요인으로 치태가 치주낭 내에 축적되면 주변에 존재하는 혐기성 그람음성 세균들의 서식처가 되어, 치주낭의 심부로 증식되게 된다. 이때 증식된 혐기성 그람음성 세균의 독소 및 모든 산물이 직접 조직을 파괴하거나 면역계를 자극하여 자극된 면역계에서부터 여러 가지 작용이 일어나 치주조직 파괴와 더불어 염증을 유발하게 된다. 이에 대한 방어기전으로서 다형핵 백혈구의 기능과 면역반응이 전신적인 요인으로서 작용하게 된다.There are many causes of periodontal disease, but when the plaque accumulates in the periodontal pocket due to local factors, it becomes a habitat of anaerobic Gram negative bacteria present in the surrounding area and proliferates to the deep part of the periodontal pouch. At this time, the toxins and all products of the anaerobic Gram-negative bacteria that are proliferated directly destroy the tissue or stimulate the immune system and stimulate the immune system, resulting in various actions and inflammation along with periodontal tissue destruction. The function and immune response of the polymorphonuclear leukocyte function as a systemic factor before the defense period.
치주질환의 치료는 환자의 개선된 구강위생의 확립, 비외과적 혹은 외과적인 치석제거술, 치근활택술, 치은소파술과 신부착을 응용한 치주조직의 재생술들이 이용되어 왔다. 그러나 이런 외과적인 치료 방법은 치료를 위해 치과를 가야하는 번거로움으로 인해 효과적인 치료가 어렵고 또한 병의 예방보다는 병이 어느 정도 진행되었을 경우 행하는 치료에 국한되어 있어, 치료를 하지 않을 경우 만성질환으로 진행되는 경우가 대부분이다. Treatment of periodontal disease has been based on the establishment of improved oral hygiene in patients, non-surgical or surgical calculus removal, root resorption, gingival curettage and periodontal tissue regeneration. However, these surgical treatment methods are difficult to effectively treat due to the inconvenience of going to the dentist for treatment, and they are limited to the treatment that is performed when the disease progresses to some extent rather than to the prevention of the disease. .
부가적인 치료로 전신적인 항생제의 복용과 국소 서방형 제재가 사용되어 왔으나, 불필요한 부위에도 약물이 너무 많이 전달되어 그로 인한 부작용과 최근 사용되는 항생제 에 대한 내성을 나타내는 치주질환균이 분리된 예가 보고되고 있어 심각한 문제점을 안고 있다. The use of systemic antibiotics and local controlled release agents have been used as adjunctive therapies. However, there has been reported a case in which periodontal disease bacteria, which are resistant to antibiotics recently used, There is a serious problem.
이러한 외과적 치료의 한계성과 항생제 사용의 문제점을 보완하고 치주질환 예방 및 치료효과를 발현하기 위해서는 파괴 및 소실된 치주조직을 원상회복시키는 활성을 지닌 제제의 출현이 필요하였다. 또한 종래 치료제에 의한 내성이나 안전성 문제를 극복할 수 있는 치료제의 개발이 필요하다.In order to overcome the limitations of such surgical treatment and to solve the problems of antibiotic use and manifest the effect of prevention and treatment of periodontal disease, it was necessary to produce a preparation having a function of recovering the damaged and lost periodontal tissue. It is also necessary to develop a therapeutic agent capable of overcoming resistance and safety problems caused by conventional therapeutic agents.
본 발명의 목적은 김 추출물을 포함하는 치주 질환 예방 및 치료용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for the prevention and treatment of periodontal disease including a Kim extract.
본 발명의 다른 목적은 김 추출물을 이용하여, 치은섬유아세포(HGF-1, Human Gingival Fibroblast-1)의 염증을 완화할 수 있는 치주 질환 예방 및 치료용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for the prevention and treatment of periodontal disease which can alleviate inflammation of gingival fibroblast (HGF-1, Human Gingival Fibroblast-1) using a Kim extract.
본 발명의 또 다른 목적은 상기 치주 질환 예방 및 치료용 조성물을 포함하는 구강 청결용 조성물, 구강 청결제, 치약 및 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide an oral cleaning composition, oral cleaning agent, dentifrice and food composition containing the composition for preventing and treating periodontal disease.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 치주 질환 예방 및 치료용 조성물은 김 추출물을 유효성분으로 포함하며, 치은섬유아 세포(HGF-1, Human Gingival Fibroblast-1)의 염증 완화 효과가 우수한 것을 특징으로 한다. In order to achieve the above object, the composition for the prevention and treatment of periodontal disease according to one embodiment of the present invention comprises an extract of Kim as an active ingredient and is used as an anti-inflammatory agent for gingival fibroblast (HGF-1, Human Gingival Fibroblast-1) And the effect is excellent.
상기 김 추출물은 물, 탄소수 1 내지 6의 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매로 추출될 수 있다.The Kim extract may be extracted with a solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms, and mixtures thereof.
상기 치주 질환 예방 및 치료용 조성물은 미역(Undaria pinnatifida), 다시마(Laminaria japonica), 참홑파래(Monostroma nitidum Wittrock), 청각(Codium fragile (Suringar) Hariot), 기둥 청각(Codium cylindricum Holmes) 및 이들의 혼합물로 이루어진 군으로부터 선택된 해조류 추출물을 추가로 포함할 수 있다.The composition for the prevention and treatment of periodontal disease may be selected from the group consisting of Undaria pinnatifida, Laminaria japonica, Monostroma nitidum Wittrock, Codium fragile (Suringar) Hariot, Codium cylindricum Holmes, ≪ RTI ID = 0.0 > a < / RTI > algae extract.
상기 치주 질환 예방 및 치료용 조성물은 소엽(Perilla frutescens var. acuta Kudo) 추출물을 추가로 포함할 수 있다.The composition for the prevention and treatment of periodontal disease may further comprise an extract of Perilla frutescens var. Acuta Kudo.
상기 치주 질환 예방 및 치료용 조성물은 벼룩이자리(Arenaria serpyllifolia L.) 추출물을 추가로 포함할 수 있다.The composition for the prevention and treatment of periodontal disease may further comprise an extract of Fleas (Arenaria serpyllifolia L.).
본 발명의 다른 일 실시예에 따른 구강 청결용 조성물은 상기 김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물을 포함한다.The composition for oral care according to another embodiment of the present invention includes the composition for preventing and treating periodontal disease including the extract of Kim.
본 발명의 다른 일 실시예에 따른 구강 청결제는 상기 김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물을 포함한다.The oral cleaning agent according to another embodiment of the present invention includes the composition for preventing and treating periodontal disease including the extract of Kimchi.
본 발명의 다른 일 실시예에 따른 치약은 상기 김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물을 포함한다.The toothpaste according to another embodiment of the present invention includes the composition for preventing and treating periodontal disease including the extract of Kimchi.
본 발명의 다른 일 실시예에 따른 식품용 조성물은 상기 김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물을 포함한다.The composition for food according to another embodiment of the present invention includes a composition for prevention and treatment of periodontal disease including the extract of Kim.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 치주 질환 예방 및 치료용 조성물은 우뭇가사리(Gelidium amansii) 추출물을 유효성분으로 포함한다. The composition for preventing and treating periodontal disease according to one embodiment of the present invention includes Gelidium amansii extract as an active ingredient.
상기 김 추출물은 치은섬유아 세포(HGF-1, Human Gingival Fibroblast-1)의 염증 완화 효과가 우수한 것을 특징으로 하며, 이러한 치은섬유아 세포의 염증에 대한 항염 효과로 인해, 치주 질환 예방 및 치료 효과를 나타낼 수 있다. The Kim extract is characterized by having excellent anti-inflammatory effect of gingival fibroblast (HGF-1, Human Gingival Fibroblast-1). Since the anti-inflammatory effect against inflammation of gingival fibroblast, Lt; / RTI >
상기 김(Porphyra tenera)는 해태(海苔)라고도 하고 바다의 암초에 이끼처럼 붙어서 자란다. 긴 타원 모양 또는 줄처 럼 생긴 달걀 모양이며 가장자리에 주름이 있다. 붉은 갈색과 파란빛을 띤 녹색이다. 탄수화물인 한천이 가장 많이 들어 있으며, 헤미셀룰로오스(hemicellulose), 소르비톨(sorbitol) 및 둘시톨(dulcitol) 등이 들어 있다. 지방은 거의 없으나 단백질은 30-40% 들어있다. 특히 트레오닌(Threonine) 발린(Valine), 로이신(Leucine), 이소로이신(Isoleucine), 리신(Lysine), 메티오닌(Methionine), 페닐알라닌(Phenylalanine) 및 트 립토판(Tryptophan) 등의 필수아미노산이 많이 들어있다. 특히 달콤한 맛과 기름진 맛이 나는 아미노산인 글리신(Glycine) 및 알라닌(Alanine)이 들어 있어 감칠맛을 낸다.Porphyra tenera, also known as sea grass, grows on the reef of the sea like moss. Long oval or oval shape with wrinkles on the edges. It is reddish brown and blueish green. The carbohydrate agar is the most abundant and contains hemicellulose, sorbitol and dulcitol. Almost no fat, but 30-40% protein. In particular, it contains many essential amino acids such as threonine valine, leucine, isoleucine, lysine, methionine, phenylalanine and Tryptophan . Glycine and alanine, which are especially sweet and oily amino acids, are contained in this product.
상기 김은 당업계에 공지된 추출 및 분리하는 방법을 사용하여 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 '추출물'은 적절한 용매를 이용하여 김으로부터 추출 한 것이며, 예를 들어, 김의 열수추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함할 수 있다The Kim extract may be obtained by extracting and isolating from nature using extraction and isolation methods known in the art, and the 'extract' defined in the present invention is extracted from Kim using an appropriate solvent, For example, a hot water extract of Kim, a polar solvent-soluble extract or a non-polar solvent-soluble extract
보다 구체적으로, 상기 김 추출물은 물, 탄소수 1 내지 6의 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매로 추출한 것으로, 상세하게는 에탄올을 추출용매로 추출한 김 에탄올 추출물일 수 있으며, 보다 상세하게는 75% 에탄올을 추출용매로 이용하여 추출한 김 추출물일 수 있으나, 상기 예시에 국한되는 것은 아니다. More specifically, the Kim extract is extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, and a mixture thereof. Specifically, the extract may be an extract of Kim extract obtained by extracting ethanol with an extraction solvent. 75% ethanol as an extraction solvent, but it is not limited to the above example.
한편 상기 김 추출물은 김을 사용하여 추출물을 제조한 뒤 이를 발효한 것일 수 있다. 상기 김 추출물을 발효하는 경우, 안정성이 우수하여, 보관성이 향상되고, 상대적으로 높은 농도에서 안정적으로 사용할 수 있는 장점이 있다.On the other hand, the above-mentioned Kim extract can be obtained by fermenting an extract after preparing an extract using Kim. When fermenting the above extract, the stability is excellent, the storage stability is improved, and it is advantageously used stably at a relatively high concentration.
상기 발효에 사용하는 미생물로는 락토바실러스 살리바리우스(Lactobacillus salivarius), 락토바실러스 아시도필루스(Lactobacillus acidophilus), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 람노수스(Lactobacillus rhamnosus), 락토바실러스 플랜타룸(Lactobacillus plantarum), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘툼(Lactobacillus fermentum), 락토바실러스 파라카세이(Lactobacillus paracasei), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 델브루에키(Lactobacillus delbrueckii), 락토바실러스 레우테리(Lactobacillus reuteri), 락토바실러스 부츠네리(Lactobacillus buchneri), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 존스니(Lactobacillus johonsonii), 락토바실러스 케피르(Lactobacillus kefir) 등과 같은 유산 바실리, 락토코코스 락티스(Lactococcus lactis), 락토코코스 플랜타룸(Lactococcus plantarum), 락토코코스 라피노락티스(Lactococcus raffinolactis), 엔테로코코스파에칼리스(Enterococcus faecalis), 엔테로코코스 파에시늄(Enterococcus faecium), 스트렙토코코스 터모필리우스(Streptococcus thermophilus), 류코노스톡락티스(Leuconostoc lactis), 류코노스톡 메센테로이드(Leuconostoc mesenteroides) 등과 같은 유산 콕사이 및 비피도박테리움 애닐멀스(Bifidobacterium animals), 비피도 박테리움 비피듐(Bifidobacterium bifidum),비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 인판티스(Bifidobacterium infantis), 비피도바테리움 롱굼(Bifidobacterium longum), 비피도박테리움 수도롱굼(Bifidobacterium pseudolongum), 비피도박테리움 터모필룸(Bifidobacterium themophilum), 비피도박테리움 아돌센티스(Bifidobacterium adolescentis) 등과 같은 비피도박테리아를 포함할 수 있으며, 더욱 바람직하게는 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 람노수스(Lactobacillus rhamnosus), 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스균, 비피도 박테리움 브레브(Bifidobacterium breve) 비피더스균, 및 락토바실러스 아시도 필루스(Lactobacillus acidophilus)로 이루어진 군에서 선택되는 하나 이상인 것일 수 있다.Examples of the microorganism used for the fermentation include Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus plantarum Lactobacillus plantus, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus delbrueckii, Such as Lactobacillus reuteri, Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii, Lactobacillus kefir, and the like, lactic acid bacteria such as lactobacillus kefir, Lactococcus lactis, Lactococcus plantarum, Lactococcus raffinolactis, Enterococcus faecalis, Enterococcus faecium, Streptococcus thermophilus, Streptococcus spp. Bifidobacterium bifidum, Bifidobacterium bifidum, Bifidobacterium bifidum, and Bifidobacterium bifidum, such as Leuconostoc lactis, Leuconostoc mesenteroides, and the like, Bifidobacterium species such as Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium themophilum, Bifidobacteria such as Bifidobacterium adolescentis, and the like, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum bifidobacterium, Bifidobacterium breve bifidobacterium, and Lactobacillus species such as Lactobacillus casei, Lactobacillus rhamnosus, And Lactobacillus acidophilus. ≪ Desc /
상기 치주 질환 예방 및 치료용 조성물은 김 추출물 이외에, 미역(Undaria pinnatifida), 다시마(Laminaria japonica), 참홑파래(Monostroma nitidum Wittrock), 청각(Codium fragile (Suringar) Hariot), 기둥 청각(Codium cylindricum Holmes) 및 이들의 혼합물로 이루어진 군으로부터 선택된 해조류 추출물을 추가로 포함할 수 있다. The compositions for prevention and treatment of periodontal disease may further contain other ingredients such as undaria pinnatifida, Laminaria japonica, Monostroma nitidum Wittrock, Codium fragile (Suringar) Hariot, Codium cylindricum, And mixtures thereof. ≪ RTI ID = 0.0 > [0040] < / RTI >
상기 미역(Undaria pinnatifida)은 갈조식물문(Phaeophyta) 갈조강(Phaeophyceae) 다시마목(Laminariales) 미역과(Alariaceae)에 속하는 해조류로, 기부는 수지상이고, 줄기는 편원이며, 그 상부는 엽상부의 중륵으로 되고 잎은 자우에 우상열편을 가진다. 우리나라와 일본에 분포하며, 우리나라에서는 서해안의 백령도에서 동해안 끝에 이르기까지 넓은 영역에 분포하며, 부산, 완도 등 남해안 일대에서 양식하고, 우리나라와 일본에서 예로부터 식용되었왔다.Undaria pinnatifida is an algae belonging to Phaeophyceae Lamaariaceae (Alariaceae). Its base is dendritic, its stem is an eggplant, its upper part is the midrib The leaf has the right upper lobe on the chow. It is distributed in Korea and Japan. It is distributed in a wide area from Baekryeong Island on the west coast to the end of the east coast in Korea. It has been cultivated in the southern coastal areas of Busan and Wando and has been edited in Korea and Japan.
상기 다시마(Laminaria japonica)는 갈조식물문(Phaeophyta) 갈조강(Phaeophyceae) 다시마목(Laminariales) 다시마과(Laminariaceae)에 속하는 해조류로, 외관상 엽상부, 줄기, 뿌리로 구분되며, 엽상부는 띠모양으로 길고, 엽상부의 중앙부분은 두터운 중대부(中帶部)를 이루며, 중대부의 양가는 세로로 흠이 있다. 줄기는 보통 원주상이며 직립하며, 뿌리는 줄기의 하부에서 차상으로 분지하는 수지상의 형태를 나타낸다. 상기 다시마는 예로부터 우리나라를 비롯한 일본, 중국에서 식용으로 널리 사용되어 왔다.The seaweed (Laminaria japonica) is a seaweed belonging to Phaeophyta, Phaeophyceae, Laminariales, Laminariaceae, and is apparently divided into lobes, stems and roots. The lobes are long, The central part of the foliage forms a thick middle part, and the middle part has a vertical flaw. The stem is usually circumferential and upright, and the root represents the dendritic shape branched from the bottom of the stem. The kelp has been widely used for edible purposes in Japan and China, including Korea.
상기 참홑파래(Monostroma nitidum Wittrock)는 우리나라의 남해안 및 제주도에 주로 분포하며, 동해 연안에서는 울릉도와 포항 영일만 등지에 분포한다. 몸은 막상의 엽체로 연약하며 체형은 불규칙하고 주름이 있다. 엽체의 색깔은 선록색으로 광택을 띠기도 한다. 크기는 2 내지 10츠 내외이지만, 때로는 20츠 이상으로 자라는 엽체도 있다. 파도가 조용한 조간대의 상부에서 많이 자라며 군락을 이룬다.Monostroma nitidum Wittrock is distributed mainly in the southern coast and Jeju Island in Korea and is distributed in Ulleungdo and Pohang Youngil Bay in the East Sea coast. The body is fragile with lanceolate, irregular and wrinkled. The color of the leaves may be lustrous and lustrous. The size is about 2 to 10 ts, but sometimes there are foliage that grows more than 20 ts. The waves grow in the upper part of the quiet intertidal zone and form a community.
상기 청각(Codium fragile (Suringar) Hariot)은 우리나라 전 연안의 조하대에서 발견되는 종이다. 몸은 원주상으로 직립하며, 다소 균일하게 가지가 분지한다. 어린 것은 전면에 털이 있으나 후에 떨어진다. 조간대에서 수심이 깊은 조하대의 바위 위에서 생육한다. 크기는 10 내지 30cm, 굵기는 1.5 내지 3mm 내외이고, 하부는 상부에 비해 좀 더 굵다.The abovementioned auditory (Codium fragile (Suringar) Hariot) is a species found in the lower part of Korea. The body is upright on the circumference and branch branches more or less uniformly. The young ones have hairs on the front but fall behind. It grows on the rocks of Jodai-dong, which is deep in the intertidal zone. The size is 10 to 30 cm, the thickness is about 1.5 to 3 mm, and the lower part is thicker than the upper part.
상기 기둥 청각(Codium cylindricum Holmes)은 우리나라 남해안에서 주로 발견되는 종으로 동해안에서는 독도, 부산시 기장 등에서 생육한다. 몸은 굵고 길게 자라며, 규칙적으로 두갈래로 분지하는 특징이 있다. 몸은 전체적으로 원주상이지만, 분지한 부분은 편평하게 된다. 체색은 황록색으로 다육질이며, 대지에서 건조시키면 옆은 녹색으로 보이는 특징을 띤다. 저조선 부근에서 조하대에 생육한다. 파도의 영향이 크지 않은 조용한 곳을 선호하며, 크기는 1m 이상으로 자라는 경우도 있으며 굵기는 1cm 정도이다.Codium cylindricum Holmes is a species found mainly in the southern coast of Korea. It grows in Dokdo, Busan, and other places on the East Sea. The body grows thick and long, and it has the feature of branching in two branches regularly. The body is entirely circumferential, but the branches become flat. Body color is yellowish green and fleshy, and when dried on the earth, the side looks green. It grows in the lower part near the low level. I prefer a quiet place where the influence of the waves is not great, and sometimes the size grows more than 1m and the thickness is about 1cm.
바람직하게는 김 추출물, 참홑파래 추출물, 청각 추출물 및 기둥 청각 추출물을 포함할 수 있다. Preferably, it may include a Kim extract, a Chrysanthemum morifolium extract, an auditory extract, and a pillar auditory extract.
상기 김 추출물을 단독으로 사용하는 경우에 비해, 상기 해조류 추출물을 추가로 포함함에 따라, 구성 성분의 혼합 사용에 따라, 치은섬유아 세포에 대한 항염증 효과가 상승할 수 있다. The anti-inflammatory effect on the gingival fibroblasts can be increased by the use of the components in combination with the above-mentioned seaweed extract, as compared with the case of using the above-mentioned Kim extract alone.
본 발명의 치주 질환 예방 및 치료용 조성물은 치은섬유아 세포에 대한 항염증 효과를 더욱 상승시키기 위해, 상기 해조류 추출물 이외에 소엽(Perilla frutescens var. acuta Kudo) 추출물 및 벼룩이자리(Arenaria serpyllifolia L.) 추출물을 추가로 포함할 수 있다. In order to further enhance the anti-inflammatory effect against gingival fibroblasts, the composition for preventing and treating periodontal disease of the present invention may further comprise a perilla extract (Perilla frutescens var. Acuta Kudo) and a flea venom (Arenaria serpyllifolia L.) Extracts may be further included.
상기 소엽(Perilla frutescens var. acuta Kudo)은 재배하는 일년초로 높이 60 내지 90cm이고 사각이며 곧추 자라고 긴 털이 있다. 잎은 대생하고 잎자루가 길며 난형이고 예두 예저이며 맥 위에 긴 털이 있고 가장자리에 톱니가 있다. 꽃은 연한 자주색으로 8 내지 9월에 가지와 원줄기 끝에 총상화서로 달린다. 열매는 분과로 꽃받침 안에 들어 있다.The perilla leaf (Perilla frutescens var. Acuta Kudo) is a cultivated annual plant, 60 to 90 cm high, square, with straight, long hairs. Leaves are larvae, long petiole, ovate, acute ears, long hairs on veins, sawtooth on edge. Flowers are light purple, hanging on branches and main stem at 8 to 9 months. The fruit is in the calyx in the calyx.
상기 벼룩이자리(Arenaria serpyllifolia L.)는 양지바른 곳에 자라는 1 내지 2년생 잡초로 높이 10 내지 25cm이고 원줄기는 밑에서부터 많이 갈라진다. 잎은 대생하고 잎자루가 없으며 난형 또는 넓은 타원형이고 양끝이 좁다. 꽃은 백색으로 4 내지 5월에 잎겨드랑이에서 화병이 나와 취산화서로 달린다. 종자는 신장형이며 짙은 갈색이다.The flea spot (Arenaria serpyllifolia L.) is a 1-2 year old weed growing in a sunny place, 10-25cm high, and the main stem divides a lot from the bottom. Leaves are larvae, petiole free, oval or wide oval, and both ends are narrow. The flower is white, and in April to May, the vase comes out from the axil of the leaf and runs on the acupuncture points. Seed is elongate and dark brown.
상기 해조류 추출물에, 항염증 효과가 우수한 소엽 추출물 및 치주염 완화에 효과가 우수한 벼룩이자리 추출물을 추가로 혼합함에 따라, 각 구성성분 간의 상호 작용에 의해, 치은섬유아 세포에 대한 항염증 효과 상승하고, 결과적으로 치주 질환 예방 및 치료에 보다 우수한 효과를 나타낸다. As a result of further intercalation of the flea weevil extract, which is effective for alleviating periodontal disease, and the lyophilized extract excellent in anti-inflammatory effect, the anti-inflammatory effect against gingival fibroblasts is increased , And as a result, it exhibits superior effects for prevention and treatment of periodontal disease.
바람직하게 상기 치주 질환 예방 및 치료용 조성물은 김 추출물을 포함하며, 상기 김 추출물 100 중량부에 대하여, 참홑파래 추출물 50 내지 80 중량부, 청각 추출물 30 내지 50 중량부, 기둥 청각 추출물 30 내지 50 중량부, 소엽 추출물 20 내지 50 중량부 및 벼룩이자리 추출물 20 내지 50 중량부로 포함할 수 있다. 상기 범위에 의하는 경우 각 추출물의 상호 작용에 의한 상승효과로 임계적 의의가 있는 정도의 상승효과가 발현되며, 상기 범위를 벗어나는 경우 상승효과가 급격히 저하되거나 거의 없게 된다.Preferably, the composition for preventing and treating periodontal disease comprises a Kim extract, wherein 50 to 80 parts by weight of a chrysanthemum chinensis extract, 30 to 50 parts by weight of a chrysanthemum extract, 30 to 50 parts by weight of a chrysanthemum extract, 20 to 50 parts by weight of the extract, 20 to 50 parts by weight of the flea spot extract. In the above range, a synergistic effect with a critical significance is expressed by the synergistic effect due to the interaction of the respective extracts, and when the concentration is outside the above range, the synergistic effect is significantly lowered or hardly occurs.
본 발명의 식품의 종류에는 특별한 제한은 없다. 상기 추출 혼합물을 첨가할 수 있는 건강기능식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있고, 통상적인 의미에서의 건강기능식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.The kind of the food of the present invention is not particularly limited. Examples of the health functional food to which the above extraction mixture can be added include meat products, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen noodles, other noodles, gums, dairy products including ice cream, , A drink, an alcoholic beverage, and a vitamin complex, and may include foods used as food for animals, which may include all health functional foods in the conventional sense. In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
본 발명의 치약 조성물, 구강청정제(가글) 및 구강 스프레이은 약효 성분으로서 약효 성분으로서 충치 예방제인 불화나트륨, 불화 인산나트륨, 불화아민, 불화주석 또는 크실리톨; 살균제인 클로로헥시딘, 세틸피리디움 클로라이드 또는 트리클로산; 생약제인 죽염 또는 프로폴리스; 염증 완화제인 알란토인, 아미노카프론산, 트라넥사민산, 초산토코페롤 또는 메틸설포닐메탄; 및 효소제인 덱스트라나제, 글루코스옥시다제, 글루코아밀라제, α,β-아밀라제, 락토퍼옥시다제 및 라이소자임으로 이루어진 군에서 선택되는 어느 하나 이상의 성분을 추가로 포함할 수 있다.The dentifrice composition, mouthwash (goggle) and oral spray of the present invention can be used as a medicinal active ingredient as a dentifrice preventive agent such as sodium fluoride, sodium fluorophosphate, fluorinated amine, tin fluoride or xylitol; Chlorhexidine, cetylpyridinium chloride or triclosan, which are bactericides; Bamboo salt or propolis; Inflammatory emollients such as allantoin, aminocaproic acid, tranexamic acid, tocopherol acetate or methylsulfonylmethane; And one or more components selected from the group consisting of enzymes dextranase, glucose oxidase, glucoamylase,?,? -Amylase, lactoperoxidase and lysozyme.
또한, 본 발명의 치약 조성물, 구강 청정제 및 구강 스프레이는 연마제, 습윤제, 결합제, 기포제, 감미제, 음이온성 계면 활성제, 향료 및 색소로 이루어진 군에서 선택된 어느 하나 이상의 물질을 추가로 포함할 수 있다. 상기 조성물의 형태 는 페이스트상, 분말상, 액상(가글형태) 또는 분문상의 형태일 수 있다.In addition, the dentifrice composition, oral cleaning agent and oral spray of the present invention may further comprise at least one substance selected from the group consisting of abrasives, wetting agents, binders, foaming agents, sweeteners, anionic surfactants, perfumes and pigments. The form of the composition may be in the form of paste, powder, liquid (goggle type) or powder form.
상기와 같이, 본 발명의 치주 질환의 예방 및 치료용 조성물을 식품용 조성물 또는 구강 청결제용 조성물로 이용할 경우, 해조류 추출물의 고유의 비린 맛 및 텁텁함으로 인해 기호성이 떨어지는 문제가 발생할 수 있다. 또한, 소엽 추출물 및 벼룩이자리 추출물의 쓴맛도 문제될 수 있다. As described above, when the composition for the prevention and treatment of periodontal disease of the present invention is used as a composition for food or a composition for oral cleanser, there is a problem that the palatability of the seaweed extract may be poor due to its pungent taste and toughness. In addition, the bitter taste of the lobular extract and flea-littion extract may be problematic.
이에, 본 발명에서는 기호성이 떨어지는 문제를 방지하고, 치주 질환의 예방 및 치료 효과를 보다 상승시키기 위해, 감초(Glycyrrhiza uralensis) 추출물, 및 전동싸리(Yellow melilot) 추출물을 추가로 소량 포함할 수 있다.Accordingly, in order to prevent the problem of poor palatability and to further enhance the preventive and therapeutic effect of periodontal disease, the present invention may further include a small amount of Glycyrrhiza uralensis extract and Yellow melilot extract.
상기 감초(Glycyrrhiza uralensis)는 콩과 유럽감초, 만주감초, 기타 동속식물의 뿌리 및 근경으로, 봄과 가을에 채취해 수염 뿌리를 제거하고 볕에 말려 사용한다. 성질은 평이하고 맛이 달다. 생용하면 해동하는 성질이 있어 창양, 종독, 인후종통, 식중독을 치료할 수 있다. 또한 약을 조화시키는 성질이 있어 약의 준렬한 성질을 감쇄시킨다. 복통, 설사, 노권, 심계, 경간, 폐위 등을 치료할 수 있다.The licorice (Glycyrrhiza uralensis) is a root and rootstock of soybean, European licorice, Manchuria licorice, and other herbaceous plants. It is collected in spring and autumn, and the beard roots are removed and sun dried. The nature is plain and the taste is sweet. It has the property of thawing when it is used, and it can treat Changyang, Tonghodok, Throat, and food poisoning. It also has the property of harmonizing the drug to attenuate the quasi-rugged nature of the drug. Abdominal pain, diarrhea, heart disease, heart palpitations, span, and lung can be treated.
상기 전동싸리(Yellow melilot)는 초목서(草木犀)·멜리토우스초라고도 한다. 중국 북부 원산이다. 저지대의 풀밭에 자란다. 높이 60 내지 90cm이고 가지가 갈라지며 마르면 향기가 난다. 어릴 때는 털이 있으나 후에 없어진다. 잎은 어긋나고 3개의 작은잎으로 된 겹잎이다. 작은잎은 긴 타원형 또는 거꾸로 선 바소꼴이며 가장자리에 잔 톱니가 있다. 그리고 꽃은 7 또는 8월에 피고 노란색이며 가지 끝이나 잎겨드랑이에서 총상으로 빽빽하게 달린다. 꽃받침에는 잔 털이 있다. 열매는 달걀 모양이며 털이 없고 검게 익는다. 풀 전체를 해열·안질·신장염 등에 약용한다. 꽃이 보다 작고 흰색인 것을 흰전동싸리(M. alba)라고 한다. 모두 목초자원으로 재배하던 것이 번져서 야생으로 자란다.The above-mentioned Yellow melilot is also called a melon. It is the northern part of China. It grows in low-lying meadows. It is 60 to 90 cm high and branches are split and smelled when dried. There are hairs in my childhood, but they disappear later. Leaves are alternate phyllotaxis of three small leaves. Leaves are long oval or inverted, and have small sawtooth edges. The flower blooms in July or August and it is yellow, and it runs tightly with gunshot at the tip of the branch or the axilla. Calyx has hairy hairs. The fruit is egg-shaped, has no hair, and is black. The entire paste is used for heat, heat, nephritis, etc. It is called white algae (M. alba) that flowers are smaller and white. Everything that grows as a grass resource grows wild and grows.
상기 감초 추출물 및 전동싸리 추출물은 소량 포함되어, 치주 질환의 예방 및 치료용 조성물의 기호도를 상승시키고, 구성 성분과의 혼합 사용에 의해, 치은섬유아 세포에 대한 항염증 효과를 상승시킬 수 있다. The licorice extract and the electric sphygmomanometer extract are contained in a small amount to increase the preference of the composition for the prevention and treatment of periodontal disease and increase the anti-inflammatory effect on the gingival fibroblast by mixing with the constituents.
바람직하게는, 본 발명의 치주 질환 예방 및 치료용 조성물은 상기 김 추출물 100 중량부에 대하여, 참홑파래 추출물 50 내지 80 중량부, 청각 추출물 30 내지 50 중량부, 기둥 청각 추출물 30 내지 50 중량부, 소엽 추출물 20 내지 50 중량부, 벼룩이자리 추출물 20 내지 50 중량부, 감초 추출물 10 내지 20 중량부 및 전동싸리 추출물 1 내지 5 중량부로 포함할 수 있다. 상기 범위에 의하는 경우 각 추출물의 상호 작용에 의한 상승효과로 임계적 의의가 있는 정도의 상승효과가 발현되며, 상기 범위를 벗어나는 경우 상승효과가 급격히 저하되거나 거의 없게 된다.Preferably, the composition for preventing and treating periodontal disease according to the present invention comprises 50 to 80 parts by weight of a chrysanthemum chinensis extract, 30 to 50 parts by weight of a chrysanthemum extract, 30 to 50 parts by weight of a chrysanthemum extract, 20 to 50 parts by weight of a leaf extract, 20 to 50 parts by weight of a flea spot extract, 10 to 20 parts by weight of a licorice extract, and 1 to 5 parts by weight of an electric sirate extract. In the above range, a synergistic effect with a critical significance is expressed by the synergistic effect due to the interaction of the respective extracts, and when the concentration is outside the above range, the synergistic effect is significantly lowered or hardly occurs.
본 발명의 김 추출물을 포함하는 치주 질환 예방 및 치료용 조성물에 의하면 치은섬유아세포(HGF-1, Human Gingival Fibroblast-1)의 염증을 완화할 수 있는 치주 질환의 예방 및 치료 효과가 우수하다.The composition for prevention and treatment of periodontal disease comprising the extract of Kimchi of the present invention is excellent in the prevention and treatment of periodontal disease which can relieve inflammation of gingival fibroblast (HGF-1, Human Gingival Fibroblast-1).
또한, 기존 항생 물질과 달리, 식용으로 사용하는 해조류 추출물 등을 이용하는 점에서, 내성 및 부작용이 문제되지 않고, 기호도가 우수한 치약, 구강 스프레이, 구강 청결제 및 츄잉검 등으로 제공할 수 있다.In addition, unlike existing antibiotics, it can be provided with dentifrices, oral sprays, oral cleansers, chewing gums and the like which have no problem of resistance and side effects and are excellent in preference in that they use algae extract or the like to be used for edible purposes.
도 1은 본 발명의 치주 질환의 예방 및 치료용 조성물을 처리한 경우의 BGF-1에서의 IL-6의 측정 결과에 관한 것이다.
도 2는 본 발명의 치주 질환의 예방 및 치료용 조성물을 처리한 경우의 BGF-1에서의 IL-1β의 측정 결과에 관한 것이다.BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph showing the results of measurement of IL-6 in BGF-1 when the composition for the prevention and treatment of periodontal disease of the present invention is treated. Fig.
Fig. 2 relates to the measurement result of IL-1? In BGF-1 when the composition for the prevention and treatment of periodontal disease of the present invention is treated.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[제조예 1: 치주 질환의 예방 및 치료용 조성물의 제조][Preparation Example 1: Preparation of composition for prevention and treatment of periodontal disease]
1. 김 추출물(PE)의 제조1. Preparation of Kim extract (PE)
김을 깨끗하게 세척하여, 완전히 건조시킨 다음 분쇄기를 이용하여 분쇄하였다. 상기 분쇄한 김에 75% 에탄올 100ml를 가하여 하루 동안 상온에서 추출하여 추출액을 제조하였다. The steaming was washed thoroughly, thoroughly dried, and then pulverized using a pulverizer. After the milling, 100 ml of 75% ethanol was added and extracted at room temperature for one day to prepare an extract.
상기 추출액을 여과하여, 수득한 여액을 감압증발기를 사용하여 감압 농축하여 김 추출물을 제조하였다. The extract was filtered, and the obtained filtrate was concentrated under reduced pressure using a vacuum evaporator to prepare a Kim extract.
2. 기타 추출물의 제조2. Preparation of other extracts
상기 김 추출물과 동일한 방법으로 참홑파래 추출물(ME), 청각 추출물(SE), 기둥 청각 추출물(HE), 소엽 추출물(FE) 및 벼룩이자리 추출물(AE)을 제조하였다.Seed extracts (ME), auditory extracts (SE), column hearing extracts (HE), leafy leaves extracts (FE) and flea spots extracts (AE) were prepared in the same manner as the above Kim extract.
3. 치주 질환의 예방 및 치료용 조성물의 제조3. Preparation of compositions for the prevention and treatment of periodontal disease
상기 김 추출물(PE), 참홑파래 추출물(ME), 청각 추출물(SE), 기둥 청각 추출물(HE), 소엽 추출물(FE) 및 벼룩이자리 추출물(AE)을 하기 표 1과 같은 조성으로 혼합하여 치주 질환의 예방 및 치료용 조성물을 제조하였다.(PE), chrysanthemum extract (ME), auditory extract (SE), column hearing extract (HE), lobule extract (FE) and flea chrysanthemum extract (AE) A composition for the prevention and treatment of periodontal disease was prepared.
(단위 중량부)(Unit weight parts)
[실험예 1: 치은섬유아세포의 염증 반응에 대한 항염증 효과][Experimental Example 1: Anti-inflammatory effect on inflammatory reaction of gingival fibroblast]
치은섬유아세포(HGF-1)에서 LPS를 처리하여 자극하여 염증 반응을 유도하였다. HGF-1의 배양은 20% FBS의 DMEM 배지를 사용하였다. 24-well plate에 HGF-1를 각 well 당 1.0×105개로 분주하고 하룻밤 동안 배양하였다. Gingival fibroblasts (HGF-1) were stimulated by treatment with LPS to induce an inflammatory response. HGF-1 was cultured in DMEM medium containing 20% FBS. HGF-1 was dispensed into a 24-well plate at a density of 1.0 × 10 5 per well and cultured overnight.
DX1 내지 DX6 시료를 DMEM 배지(with 2% FBS)로 교환하고 3시간 동안 배양해서 전처리한다. LPS(1ug/mL) 처리하여 4 시간 동안 배양하고, -80℃ stock 후 사이토카인(cytokine, IL-6, IL-1beta)측정하였다. UN은 아무런 처리를 하지 않은 것이고, CON은 LPS를 1㎍/mL를 사용한 것을 의미한다.DX1 to DX6 samples are exchanged with DMEM medium (with 2% FBS) and incubated for 3 hours for pretreatment. LPS (1 ug / mL), cultured for 4 hours, and cytokine (IL-6, IL-1beta) was measured at -80 ° C. UN means no treatment, CON means 1 μg / mL of LPS.
그 결과는 하기 도 1 및 도 2와 같다. The results are shown in FIGS. 1 and 2.
도 1 및 도 2를 참조하면, IL-1β, IL-6 모두 본 발명의 조성물에 의해 감소한 것을 확인할 수 있다. 따라서, 본 발명의 DX1 내지 DX6 조성물은 치은섬유아세포의 염증 반응에 대해 염증 완화 효과가 우수함을 확인할 수 있다.Referring to FIGS. 1 and 2, it is confirmed that both IL-1β and IL-6 are reduced by the composition of the present invention. Therefore, it can be confirmed that the DX1 to DX6 composition of the present invention has an excellent anti-inflammatory effect against the inflammatory reaction of gingival fibroblast.
[제조예 2: 혼합 조성물의 제조][Preparation Example 2: Preparation of mixed composition]
1. 감초 추출물(GE)의 제조1. Preparation of licorice extract (GE)
감초를 세척하고 건조한 뒤 이를 분쇄하였다. 상기 분쇄물을 정제수에 혼합하고 이를 2시간 동안 98 내지 100℃를 유지하고, 이를 냉각시킨 뒤 와트만 여과지로 여과하여 그 여액을 수득하였다.The licorice was washed, dried and then pulverized. The pulverized material was mixed with purified water and maintained at 98-100 ° C for 2 hours. After cooling, it was filtered with Watman filter paper to obtain a filtrate.
2. 전동싸리 추출물(TE)의 제조2. Preparation of Electrolytic Extract (TE)
상기 감초 추출물과 동일한 방법으로 전동싸리 추출물(TE)을 제조하였다.(TE) was prepared in the same manner as the licorice extract.
3. 혼합 조성물의 제조3. Preparation of mixed composition
상기 제조예 1에서 제조한 DX4 조성물에 감초 추출물(GE) 및 전동싸리 추출물(TE)를 하기 표 2와 같은 조성으로 혼합하여 치주 질환의 예방 및 치료용 조성물을 제조하였다.The composition for prevention and treatment of periodontal disease was prepared by mixing licorice extract (GE) and electrorheological extract (TE) with DX4 composition prepared in Preparation Example 1 in the composition shown in Table 2 below.
(단위 중량부)(Unit weight parts)
[실험예 2: 치은섬유아세포의 염증 반응에 대한 항염증 효과][Experimental Example 2: Anti-inflammatory effect on inflammatory reaction of gingival fibroblast]
상기 제조예 2에서 제조한 혼합 조성물에 대해서, 각 추출물의 혼합 사용에 따른 상호작용에 의한 항염증 효과의 상승 여부를 확인하기 위하여, 치은섬유아세포의 염증 반응에 대해, 항염증 효과를 미리 확인한 DX4 조성물과 비교 평가를 진행하였다. In order to confirm the increase of the anti-inflammatory effect by the interaction of each of the extracts with the mixed composition prepared in Preparation Example 2, the anti-inflammatory effect of the gingival fibroblast was examined by using DX4 The composition and comparative evaluation were carried out.
실험예 1과 동일한 방식으로 실험을 진행하였으며, 비교 시험 결과를 보다 명확하게 나타내기 위하여, 지수를 이용하였다. 즉, DX4 조성물의 사이토카인(cytokine, IL-6, IL-1beta)측정 결과를 지수 5로 고정하고, 상기 혼합 조성물의 사용에 따른 결과를 이와 비교하여 1 내지 10의 지수로 나타내었다. 상기 지수는 그 숫자가 높을수록 치은섬유아세포의 염증 반응에 대해 염증 완화 효과가 우수함을 의미한다.Experiments were carried out in the same manner as in Experimental Example 1, and an exponent was used to show the results of the comparison test more clearly. That is, cytokine (IL-6, IL-1beta) measurement results of the DX4 composition were fixed at an index of 5, and the results of the use of the mixed composition were expressed as an index of 1 to 10 compared with the results. The higher the number, the better the anti-inflammatory effect of the gingival fibroblast's inflammatory response.
productionIL-6
production
productionIL-1?
production
(단위 지수)(Unit index)
상기 표 3에 따르면, DX4 조성물을 사용하는 경우에 비해, 혼합 조성물을 이용한 경우, 치은섬유아세포의 염증 반응에 대해, 염증 완화 효과가 일부 향상됨을 확인할 수 있다.According to the above Table 3, it can be confirmed that the inflammation-reducing effect of the gingival fibroblast is partially improved when the mixed composition is used as compared with the case of using the DX4 composition.
[실험예 3: 관능 실험][Experimental Example 3: Sensory Test]
상기 제조예 1에서 제조한 DX4의 조성물 및 제조예 2에서 제조한 TX1 내지 TX6의 조성물에 대해 구강 청결제로 이용했을 때의 관능 실험을 진행하였다.The composition of DX4 prepared in Preparation Example 1 and the composition of TX1 to TX6 prepared in Preparation Example 2 were subjected to a sensory test when used as an oral cleanser.
상기 DX4, TX1 내지 TX6의 조성물을 각 10 중량%에 물 90중량%를 혼합하여 구강 청결제로 제조 후, 성인남녀 10명에 대한 관능성 평가를 수행하였다. 관능성 평가는 청량감, 잔류감, 비릿한 맛 및 자극에 따라 1 내지 10의 지수로 평가하여 평균 지수로 구분하였고, 그 결과를 하기 표 4에 나타내었다. 10% by weight of each of the compositions of DX4 and TX1 to TX6 was mixed with 90% by weight of water to prepare an oral cleanser. Ten adult male and female subjects were then subjected to a sensory evaluation. The sensory evaluation was evaluated by an index of 1 to 10 according to a refreshing sensation, a residual sensation, a clear taste, and a stimulus.
(단위 지수)(Unit index)
상기 표 4의 결과에 따르면, DX4는 비릿한 맛에 의해, 구강 청결제로 기호성이 떨어질 수 있다. According to the results shown in Table 4, DX4 may have poor taste due to the taste of mouth as an oral cleanser.
반면, TX1 내지 TX6의 경우에는 비릿한 맛이 DX4에 비해 대폭 개선되어, 구강 청결제로의 기호도를 높일 수 있다.On the other hand, in the case of TX1 to TX6, the taste is remarkably improved as compared with DX4, and the preference for oral cleanser can be enhanced.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.
Claims (9)
치은섬유아 세포(HGF-1, Human Gingival Fibroblast-1)의 염증 완화 효과가 우수하며,
미역(Undaria pinnatifida), 다시마(Laminaria japonica), 참홑파래(Monostroma nitidum Wittrock), 청각(Codium fragile (Suringar) Hariot), 기둥 청각(Codium cylindricum Holmes) 및 이들의 혼합물로 이루어진 군으로부터 선택된 해조류 추출물을 추가로 포함하는
김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물.Kim (Porphyra Tenera) extract as an active ingredient,
Gingival fibroblasts (HGF-1, Human Gingival Fibroblast-1) have excellent anti-inflammatory effects,
Addition of algae extracts selected from the group consisting of undaria pinnatifida, Laminaria japonica, Monostroma nitidum Wittrock, Codium fragile (Suringar) Hariot, Codium cylindricum Holmes and mixtures thereof As including
A composition for the prevention and treatment of periodontal disease, comprising a Kim extract.
상기 김 추출물은 물, 탄소수 1 내지 6의 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매로 추출되는
김 추출물을 포함하는 치주 질환 예방 및 치료용 조성물.The method according to claim 1,
The Kim extract is extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, and a mixture thereof
A composition for the prevention and treatment of periodontal disease, comprising a Kim extract.
상기 치주 질환 예방 및 치료용 조성물은 소엽(Perilla frutescens var. acuta Kudo) 추출물을 추가로 포함하는
김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물.The method according to claim 1,
The composition for the prevention and treatment of periodontal disease may further comprise a Perilla frutescens var. Acuta Kudo extract
A composition for the prevention and treatment of periodontal disease, comprising a Kim extract.
상기 치주 질환 예방 및 치료용 조성물은 벼룩이자리(Arenaria serpyllifolia L.) 추출물을 추가로 포함하는
김 추출물을 포함하는 치주 질환의 예방 및 치료용 조성물.The method according to claim 1,
The composition for the prevention and treatment of periodontal disease further comprises an extract of Fleas (Arenaria serpyllifolia L.)
A composition for the prevention and treatment of periodontal disease, comprising a Kim extract.
구강 청결용 조성물.A composition for prevention and treatment of periodontal disease comprising the extract of Kimchi according to claim 1
Compositions for oral cleansing.
구강 청결제.A composition for prevention and treatment of periodontal disease comprising the extract of Kimchi according to claim 1
Oral cleanser.
치약.A composition for prevention and treatment of periodontal disease comprising the extract of Kimchi according to claim 1
toothpaste.
식품용 조성물.A composition for prevention and treatment of periodontal disease comprising the extract of Kimchi according to claim 1
Food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170180383A KR101978365B1 (en) | 2017-12-27 | 2017-12-27 | Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170180383A KR101978365B1 (en) | 2017-12-27 | 2017-12-27 | Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101978365B1 true KR101978365B1 (en) | 2019-05-14 |
Family
ID=66581235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170180383A KR101978365B1 (en) | 2017-12-27 | 2017-12-27 | Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101978365B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210039067A (en) * | 2019-10-01 | 2021-04-09 | 김성윤 | Composition for inhibiting halitosis containing seaweed extracts |
WO2022172807A1 (en) * | 2021-02-12 | 2022-08-18 | 一丸ファルコス株式会社 | Composition for oral cavity care |
WO2022203228A1 (en) * | 2021-03-25 | 2022-09-29 | 경상국립대학교산학협력단 | Composition for prevention or treatment of inflammatory diseases caused by ultrafine particulate matter comprising porphyra tenera extract as active ingredient |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960000240B1 (en) * | 1993-07-20 | 1996-01-04 | 오용호 | Machines for washing vegetables |
KR20070099126A (en) * | 2006-04-03 | 2007-10-09 | 부경대학교 산학협력단 | An extract of undaria pinnatifida having anti-inflammatory activity |
KR20100007521A (en) * | 2008-07-14 | 2010-01-22 | 한국과학기술연구원 | Compositions for prevention and treatment of inflammatory diseases containing the extracts of seaweeds as an active ingredient |
KR20110085543A (en) * | 2010-01-21 | 2011-07-27 | (주)더페이스샵 | Cosmetic composition for alleviating skin inflammation |
CN105087138A (en) * | 2015-07-28 | 2015-11-25 | 褚金霞 | Anti-inflammatory semen trichosanthis oil |
KR20160013805A (en) * | 2014-07-28 | 2016-02-05 | 경희대학교 산학협력단 | Composition comprising the extract of Hizikia Fusiforme for treating periodontal disease |
KR101592549B1 (en) | 2015-06-29 | 2016-02-18 | 김용수 | Composition for treating and preventing periodontal disease and caries |
KR20170042390A (en) * | 2015-10-08 | 2017-04-19 | 제주대학교 산학협력단 | Antiinflammatory compositions containing Steron Fraction of Pyropia yezoensis extracts and preparing method of the same |
KR20170092975A (en) * | 2016-02-04 | 2017-08-14 | 한국식품연구원 | A composition for improving, preventing and treating of fatty liver diseases comprising porphyra tenera extract |
-
2017
- 2017-12-27 KR KR1020170180383A patent/KR101978365B1/en active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960000240B1 (en) * | 1993-07-20 | 1996-01-04 | 오용호 | Machines for washing vegetables |
KR20070099126A (en) * | 2006-04-03 | 2007-10-09 | 부경대학교 산학협력단 | An extract of undaria pinnatifida having anti-inflammatory activity |
KR20100007521A (en) * | 2008-07-14 | 2010-01-22 | 한국과학기술연구원 | Compositions for prevention and treatment of inflammatory diseases containing the extracts of seaweeds as an active ingredient |
KR20110085543A (en) * | 2010-01-21 | 2011-07-27 | (주)더페이스샵 | Cosmetic composition for alleviating skin inflammation |
KR20160013805A (en) * | 2014-07-28 | 2016-02-05 | 경희대학교 산학협력단 | Composition comprising the extract of Hizikia Fusiforme for treating periodontal disease |
KR101592549B1 (en) | 2015-06-29 | 2016-02-18 | 김용수 | Composition for treating and preventing periodontal disease and caries |
CN105087138A (en) * | 2015-07-28 | 2015-11-25 | 褚金霞 | Anti-inflammatory semen trichosanthis oil |
KR20170042390A (en) * | 2015-10-08 | 2017-04-19 | 제주대학교 산학협력단 | Antiinflammatory compositions containing Steron Fraction of Pyropia yezoensis extracts and preparing method of the same |
KR20170092975A (en) * | 2016-02-04 | 2017-08-14 | 한국식품연구원 | A composition for improving, preventing and treating of fatty liver diseases comprising porphyra tenera extract |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210039067A (en) * | 2019-10-01 | 2021-04-09 | 김성윤 | Composition for inhibiting halitosis containing seaweed extracts |
KR102313830B1 (en) * | 2019-10-01 | 2021-10-18 | 김성윤 | Composition for inhibiting halitosis containing seaweed extracts |
WO2022172807A1 (en) * | 2021-02-12 | 2022-08-18 | 一丸ファルコス株式会社 | Composition for oral cavity care |
WO2022203228A1 (en) * | 2021-03-25 | 2022-09-29 | 경상국립대학교산학협력단 | Composition for prevention or treatment of inflammatory diseases caused by ultrafine particulate matter comprising porphyra tenera extract as active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3564382B1 (en) | Fermented product and production method therefor | |
KR101978365B1 (en) | Composition for preventing or alleviating periodontal disease comprising porphyra tenera extract | |
KR102358623B1 (en) | Food composition for improving skin condition comprising collagen peptide | |
KR20170029106A (en) | Dentifrice composition comprising extracts of fermented herb | |
KR102062542B1 (en) | A method for composition of the functional feed and compositon of the functional feed manufactured by the same | |
KR20080068160A (en) | Anti-aging cosmetic composition | |
KR101978355B1 (en) | Composition for preventing or alleviating periodontal disease comprising gelidium amansii extract | |
KR101409760B1 (en) | Comprising lactic acid fermentation product of Cirsium japonicum and Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
KR102313830B1 (en) | Composition for inhibiting halitosis containing seaweed extracts | |
KR20200083710A (en) | Composition containing an fermentation extract of zanthoxylum schinifolium as an active ingredient and its use | |
KR101796955B1 (en) | Cosmetic Composition Comprising the Extract of Mixed Fermentation with Sanguisorba Officinalis and Piper Longum Linn. showing Skin Anti-Aging and Whitening Effect, a preparation method thereof | |
KR100873180B1 (en) | An antibacterial composition comprising an extract of brown algae | |
KR101660467B1 (en) | Oral composition containing fermentative extract of lycii fructus as active ingredient | |
KR100871627B1 (en) | Composition for treating or preventing oral bacterial infection diseases comprising an extract of enteromorpha sp | |
KR102014312B1 (en) | Skin-whitening functional composition including polyopes affinis extracts | |
KR102453568B1 (en) | Composition for moisturizing and anti-inflammation comprising fermented Codium fragile extract fermented by inoculating Bacillus safensis strain | |
KR101942400B1 (en) | Soap composition and soap using the same | |
KR102308516B1 (en) | Composition for teeth whitening containing enteromorpha extracts | |
KR20230017372A (en) | Composition comprising superoxide dismutase and/or bacillus strain spores, and uses thereof for improving oral health | |
KR102218625B1 (en) | EM toothbrushing composition, a method for producing the EM toothbrushing composition, and an EM toothbrushing salt containing the same | |
KR102118102B1 (en) | Composition for preventing or alleviating periodontal disease | |
KR102350693B1 (en) | Tooth brightening composition for teeth whitening and brightness improvement activation containing lotus extracts | |
CN116327675B (en) | Herbal mouthwash containing lactobacillus sanfranciscensis and preparation method thereof | |
KR20140115229A (en) | Composition comprising oriental herbal extracts having antioxidant or whitening effect | |
KR20190094986A (en) | Composition for prevention or treatment of oral disease comprising Epimedium Herb extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |